AGIOS PHARMACEUTICALS INC

Agios Pharmaceuticals’ stock hits $37.00 amid a 12.46% rise since Oct. Learn why its cancer‑metabolism pipeline and $2.2B market cap make it a key biotech play.

Agios Pharmaceuticals (AGIO) holds steady at $37, near its 200‑day MA, amid a mixed biotech rally—offering stable growth and metabolic‑targeted cancer innovation for investors.

Agios Pharmaceuticals (AGIO) climbs 1.47% amid steady valuation, 2.2B market cap and a Rule 144 SEC filing—see how its biotech focus drives investor confidence.

Agios Pharmaceuticals climbs 4.99% to $37.18, steady gains in a quiet session, backed by a robust biotech pipeline focused on cancer metabolism.

Agios Pharmaceuticals surges 11.43% to $36.64, eclipsing its 11‑month high—driven by strong pipeline milestones, bullish technicals, and growing investor confidence.